Analysts Issue Forecasts for EIKN Q3 Earnings

Eikon Therapeutics, Inc. (NASDAQ:EIKN) – Stock analysts at HC Wainwright issued their Q3 2026 EPS estimates for shares of Eikon Therapeutics in a report released on Friday, October 16th. HC Wainwright analyst S. Nik anticipates that the company will post earnings of ($1.72) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Eikon Therapeutics’ current full-year earnings is ($7.24) per share. HC Wainwright also issued estimates for Eikon Therapeutics’ Q4 2026 earnings at ($1.82) EPS, FY2026 earnings at ($7.40) EPS, FY2027 earnings at ($8.49) EPS and FY2028 earnings at ($3.70) EPS.

Eikon Therapeutics (NASDAQ:EIKN) last posted its earnings results on Thursday, August 13th. The company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.02).

Other equities research analysts have also issued reports about the company. Weiss Ratings upgraded Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd. Mizuho upgraded Eikon Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 16th. Wedbush cut their target price on Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a research report on Friday, August 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eikon Therapeutics in a research note on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Eikon Therapeutics Stock Performance

Shares of EIKN opened at $7.70 on Tuesday. Eikon Therapeutics has a 12 month low of $6.45 and a 12 month high of $17.40. The company has a 50-day moving average price of $9.37 and a two-hundred day moving average price of $9.91.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of EIKN. BlackRock Inc. boosted its holdings in shares of Eikon Therapeutics by 29.0% in the 2nd quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock worth $55,873,000 after acquiring an additional 962,046 shares in the last quarter. State Street Corp bought a new stake in Eikon Therapeutics during the 2nd quarter worth approximately $4,621,000. Parkman Healthcare Partners LLC bought a new stake in Eikon Therapeutics during the 2nd quarter worth approximately $3,341,000. Comprehensive Financial Management LLC acquired a new stake in Eikon Therapeutics during the 2nd quarter valued at $1,517,000. Finally, Bank of New York Mellon Corp acquired a new stake in Eikon Therapeutics during the 2nd quarter valued at $624,000.

Insiders Place Their Bets

In other news, major shareholder Group Iv Gp Lp Column acquired 89,200 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were purchased at an average cost of $11.56 per share, with a total value of $1,031,152.00. Following the completion of the purchase, the insider owned 89,200 shares of the company’s stock, valued at $1,031,152. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

About Eikon Therapeutics

Eikon Therapeutics is a biotechnology company focused on discovering and developing medicines using advanced single-molecule imaging, cell biology and computational technologies. Its platform is designed to track the behavior of proteins and other molecular targets in living cells, with the goal of improving the understanding of disease biology and identifying potential drug candidates.

The company is developing a pipeline of therapeutics, including investigational treatments in areas such as oncology and other serious diseases.